15 Jan Holostem srl
Alessandro Padova, Ph.D., CEO
April 28 | 11:15am | Salone dei Cavalieri, Section 1
Modena, Italy
(Private)
Holostem srl is a commercial stage biotech company delivering life changing advanced therapeutic medicinal products for patients affected by orphan and rare diseases. Holostem srl is 100% owned by Fondazione ENEA Tech e Biomedical, a private foundation supervised by the Ministry of Business and Made in Italy and the Ministry of Health. Holostem pioneered GMP manufacturing for Advanced Therapeutic Medicinal Products. Holoclar® is the first cell therapy to receive conditional marketing authorization by EMA and MHRA in 2015. Holoclar has received full marketing approval in 2024 following a positive Phase III trial. Holostem has been recognized by the European Commission as a leader in the field of cell and gene therapy for orphan and rare therapeutic indications. Holostem project entitled “Integrated Cell and Gene Therapy Platforms” has been selected as one of the 13 EU programs to be funded under the IPCEI (Important Projects of Common European Interest).
